Sanders Morris Harris LLC acquired a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 3,750 shares of the biotechnology company’s stock, valued at approximately $472,000.
Other large investors have also added to or reduced their stakes in the company. Chevy Chase Trust Holdings Inc. bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $25,000. Orion Portfolio Solutions LLC bought a new position in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $26,000. Signaturefd LLC lifted its holdings in shares of BioMarin Pharmaceutical by 43.1% during the 1st quarter. Signaturefd LLC now owns 382 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 115 shares in the last quarter. Shine Investment Advisory Services Inc. lifted its holdings in shares of BioMarin Pharmaceutical by 199.5% during the 1st quarter. Shine Investment Advisory Services Inc. now owns 602 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 401 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in shares of BioMarin Pharmaceutical during the 1st quarter valued at about $83,000. Institutional investors and hedge funds own 96.46% of the company’s stock.
Shares of BMRN stock traded down $0.70 during trading on Thursday, reaching $128.03. 5,071 shares of the company’s stock were exchanged, compared to its average volume of 1,663,762. The company has a quick ratio of 1.72, a current ratio of 2.58 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $23.28 billion, a PE ratio of 211.03 and a beta of 1.09. BioMarin Pharmaceutical Inc. has a twelve month low of $62.88 and a twelve month high of $129.89. The firm’s fifty day moving average price is $112.10 and its 200-day moving average price is $93.50.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.32. The business had revenue of $502.07 million for the quarter, compared to analyst estimates of $468.77 million. BioMarin Pharmaceutical had a return on equity of 3.62% and a net margin of 6.31%. The firm’s revenue was up 25.3% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.32) EPS. As a group, analysts anticipate that BioMarin Pharmaceutical Inc. will post 0.43 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, insider Henry J. Fuchs sold 20,000 shares of the company’s stock in a transaction on Friday, April 24th. The stock was sold at an average price of $95.88, for a total value of $1,917,600.00. Following the transaction, the insider now directly owns 109,014 shares of the company’s stock, valued at approximately $10,452,262.32. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Jeffrey Robert Ajer sold 15,000 shares of the company’s stock in a transaction on Friday, June 19th. The shares were sold at an average price of $124.00, for a total value of $1,860,000.00. Following the completion of the transaction, the executive vice president now directly owns 63,402 shares in the company, valued at $7,861,848. The disclosure for this sale can be found here. Insiders have sold a total of 122,577 shares of company stock worth $12,051,538 over the last three months. 2.15% of the stock is owned by insiders.
Several research firms have commented on BMRN. Nomura restated a “hold” rating and issued a $77.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, April 30th. BidaskClub cut BioMarin Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Thursday, June 11th. Cfra restated a “buy” rating and issued a $115.00 target price on shares of BioMarin Pharmaceutical in a research note on Sunday, May 10th. SunTrust Banks boosted their target price on BioMarin Pharmaceutical from $109.00 to $143.00 in a research note on Thursday, June 18th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Sunday, June 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $118.67.
BioMarin Pharmaceutical Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
See Also: Understanding the two types of arbitrage
Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.